

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE AND APPOINTMENT OF LEAD INED

The board (the “**Board**”) of directors (the “**Directors**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) is pleased to announce that (i) Ms. Jing Huan (“**Ms. Jing**”) and Mr. Bai Zhizhong (“**Mr. Bai**”) have been appointed as a member of the nomination Committee (the “**Nomination Committee**”) with effect from 27 August 2025, and (ii) Mr. Bai is proposed to be appointed as the lead independent non-executive Director of the Company (the “**Lead INED**”) with effect from 27 August 2025.

The biographical details of Ms. Jing and Mr. Bai were set out in the Annual Report 2024. As at the date of this announcement, there has been no change in such information save as disclosed in this announcement.

Following the appointment of Ms. Jing, the Nomination Committee has one director of a different gender. This appointment is in response to the amended Corporate Governance Code and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited which has come into effect on July 1, 2025. The Board believes that the implementation of this change can strengthen the effectiveness and diversity of the Nomination Committee and further enhance good corporate governance practices of the Company as a whole.

Mr. Bai, currently an independent non-executive Director, a member of the audit committee, the remuneration committee, the Nomination Committee and the Internal Control and Corporate Governance Committee of the Company, has been appointed as the Lead INED for the purpose of adopting a high standard of corporate governance. The Lead INED will not have a separate or higher level of responsibility or liability relative to other independent non-executive Director (the “INEDs”) on the Board. He will serve as a channel of communication to enable shareholders to understand the actions taken by INEDs in the performance of their responsibilities, as an intermediary between Directors and shareholders and enhance the communications among the INEDs and between the INEDs and the rest of the Board.

The Board would like to extend its warm welcome to Ms. Jing and Mr. Bai in their new roles in the Board.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 27 August 2025

As at the date of this announcement, the executive Directors are Mr. Huang Xiangbin, Mr. Lei Shifeng and Mr. Huang Zhijian; the non-executive Directors is Ms. Jing Huan; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.